Odyssey Therapeutics (ODTX) Stock Price, Quote, News & History | Benzinga

SPY778.45+0.04%QQQ744.33−0.23%BTC/USD83,429.61+2.07%DIA516.18−0.33%GLD381.19−0.25%TLT78.41+0.46%

Odyssey Therapeutics Inc (ODTX) Stock Price, Quote, News & History

ODTXNASDAQ

Trade with Public

Trade with Public

$17.24

-1.02-5.59%

Last update: Oct 13, 4:00 PM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Stock Report

Key Statistics

Open

$18.18

Close

$17.24

Volume / Avg.

257.05K / 275.74K

Day Range

$17.19 - $17.25

52 Wk Range

15.10 - 29.05

Market Cap

$877.55M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

35

Short Interest

7.37%

Days to Cover

5.63

Recent Odyssey Therapeutics Inc News

This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

Analysts initiate coverage and change ratings on top stocks like ASND, DOCN, ODTX, MT, and NVCT. See their price targets and views on these stocks.

Avi Kapoor

This Oppenheimer Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Wall Street analysts changed outlook on top names: ODTX, MOBI, MANE. See analyst ratings page for all changes. MOBI target prices: $16, $19, $31

Avi Kapoor

Doximity, Aeluma, PDF Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures rise on Dow gaining 200 points. Doximity (DOCS) shares drop 21.3% after reporting mixed Q4 results and weak guidance. Other stocks also decline in pre-market trading.

Avi Kapoor

PRO
UBS Initiates Coverage On Odyssey Therapeutics with Buy Rating, Announces Price Target of $27

UBS analyst Alice Nettleton initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Buy rating and announces Price Target of $27.

Benzinga Newsdesk

PRO
Odyssey Therapeutics To Present Design Of Randomized, Double-Blind Phase 2a Trial Evaluating OD-001 In Combination With Vedolizumab In Patients With UC At ACG 2026 Annual Scientific Meeting

Odyssey Therapeutics, Inc. (NASDAQ:ODTX) ("Odyssey" or the "Company"), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and

Benzinga Newsdesk

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-132.13M

Investing Cash Flow (TTM)

-338.02M

Financing Cash Flow (TTM)

389.37M

Free Cash Flow (TTM)

-132.74M

Capital Expenditure (TTM)

-610.00K

Net Change in Cash (TTM)

-80.78M

Analyst Trends and Forecast

6

Jun

2

Aug

2

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.4

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$627.36M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

8828.44

PB Ratio (TTM)

2.08

Earnings Yield % (TTM)

-18.31%

Earnings Yield % (FWD)

-28.11%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$8.76

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$82.03M

Debt to Equity

0.06

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-